Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-29T00:18:25.373Z Has data issue: false hasContentIssue false
  • English
  • Français

Antibiotic Cycling and Marketing Into the 21st Century: A Perspective From the Pharmaceutical Industry

Published online by Cambridge University Press:  02 January 2015

Bruce S. Lavin
Bruce S. Lavin*
Affiliation:
Rhone-Poulenc Rorer Pharmaceuticals, Division of Anti-lnfectives, Collegeville, Pennsylvania
*
Anti-Infectives, US Medical Affairs, Rhone-Poulenc Rorer Pharmaceuticals, 500 Areola Rd 4C61, Collegeville, PA 19426-0998
Get access Rights & Permissions [Opens in a new window]

Abstract

Before the development of the first antimicrobial agents, bacteria already had demonstrated an ability to adapt to stress in the environment, resulting in the development of resistance that often makes the prevailing antibiotic treatment ineffective. The response to antimicrobial resistance in the medical community has been to use new or alternative antibiotics not previously used against the resistant bacteria. The pharmaceutical industry has responded to the resistance problem by producing newer antibiotics, either as modifications of currently existing compounds or as combinations of compounds that may inhibit or bypass the bacterial resistance mechanisms. The development of new antibiotics is a lengthy and costly process. To be successful, the pharmaceutical industry must anticipate the changing needs of the medical community, as well as the dynamic process of antimicrobial resistance. The marketing of new antimicrobial agents must be adaptable to the potential environmental pressures that induce bacterial resistance in order to ensure the longevity of the agents.

Type
Review
Information
Infection Control & Hospital Epidemiology , Volume 21 , Issue S1 , January 2000 , pp. S32 - S35
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Billstein, SA. How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimkrob Agents Chemother 1994;38:2679–2682Google Scholar
2.Edmond, MB, Wallace, SE, McClish, DK, Pfaller, MA, Jones, RN, Wenzel, RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239–244.Google Scholar
3.Jones, RN, Marshall, SA, Pfaller, MA, Wilke, WW, Hollis, RJ, Erwin, ME, et al. Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. The SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997;29:95–102.Google Scholar
4.Jones, RN, Ballow, CH, Biedenbach, DJ, Deinhart, JA, Schentag, JJ. Antimicrobial activity of qujmupristm-dalfopristin (RP 59500, Synercid) tested over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998;31:437–451.CrossRefGoogle Scholar
5.Hruby, DE. Bacterial adherence as a novel target for anti-infective development. In: Proceedings of Third International Antibacterial Drug Discovery & Development Summit; Princeton, NJ; March 8-9, 1999.Google Scholar
6.Gaynes, RThe impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997;11:757–765.Google Scholar
7.Pharmaceutical Manufacturers Association. Pocket Facts. Washington, DC: PMA; 1993.Google Scholar
8.Pechere, JC. Current and future management of infections due to methi-cillin-resistant staphylococci infections: the role of quinupristin/dalfo-pristin. JAntimicrobial Chemother 1999;44(suppl A):11–18.Google Scholar
9.Quale, J, Landman, D, Saurino, G, Atwood, E, DiTore, V, Patel, K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infed Dis 1996;23:1020–1025.CrossRefGoogle ScholarPubMed
10.Hershow, RC, Khayr, WF, Schreckenberger, PC. Ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibiotics. AmJTher 1998;5:213–220.Google Scholar
11.Chin, G, Marx, J. Resistance to antibiotics. Science 1994;264:359–393.Google Scholar
12.Shlaes, DM, Gerding, DN, John, JF Jr, Craig, WA, Bornstein, DL, Duncan, RA, et al. Society for Healthcare Epidemiology of America and Infectious Disease Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275–291.Google Scholar
13.McGowan, JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994;15:478–483.Google Scholar
14.Goodman, D. Workshop to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. JAMA 1996;275:1232–1240.Google Scholar
15.Gerding, DN, Larson, TA, Hughes, RA, Weiler, M, Shanholtzer, C, Peterson, LRAminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimkrob Agents Chemother 1991;35:1284–1290.Google Scholar
16.Dominguez, E. Antibiotic cycling helps hospitals cope with resistance. ASM News 1996;62:457.Google Scholar
17.Schentag, JJ, Ballow, CH, Fritz, AL, Paladino, JA, Williams, JD, Cumbo, TJ, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993;16:255–264.CrossRefGoogle ScholarPubMed
18.Kollef, MH, Vlasnik, J, Sharpless, L, Pasque, C, Murphy, D, Fraser, V. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:1040–1048.CrossRefGoogle ScholarPubMed
19.Seppala, H, Klaukka, T, Vuopio-Varkila, J, Muotiala, A, Helenius, H, Lager, K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441–446.Google Scholar